{
    "documentMetadata": {
        "title": "Varicella-Zoster Virus (Chickenpox)",
        "sourceFile": "Varicella-Zoster Virus (Chickenpox).pdf",
        "lastUpdated": "2025-02-10"
    },
    "content": [
        {
            "type": "header",
            "level": 1,
            "text": "Clinical Setting"
        },
        {
            "type": "list",
            "items": [
                "Vaccination has markedly reduced the incidence of varicella zoster virus (VZV) infections and associated morbidity (N Engl J Med 352:450, 2005; N Engl J Med 356:1338, 2007).",
                "Guidelines for varicella vaccination.",
                "Immunization schedules: adult, child age 7-18, child age 0-6.",
                "Transmission: Very contagious, via aerosolized droplets from nasopharynx",
                "Incubation period: 10-21 days",
                "Clinical syndromes (worse disease in late adolescents and adults):",
                "Chickenpox",
                "Shingles (single dermatomal or multiple dermatomes). See also, Herpes Zoster (Shingles).",
                "Disseminated VZV disease/organ involvement",
                "Emerging data suggests VZV may cause vasculopathy of cerebral, temporal, and other arteries. Suggested as possible cause of Giant Cell arteritis. Raises treatment possibilities. Need more data. Refs: Neurology 84:1948, 2015; J Infect Dis 212:S37, 2015."
            ]
        },
        {
            "type": "header",
            "level": 1,
            "text": "Etiologies"
        },
        {
            "type": "list",
            "items": [
                "Varicella-zoster virus (VZV)"
            ]
        },
        {
            "type": "header",
            "level": 1,
            "text": "Primary Regimens"
        },
        {
            "type": "list",
            "items": [
                "Immunocompetent host, chickenpox",
                "No treatment is an option for mild-moderate disease in children",
                "Valacyclovir 20 mg/kg po tid or Acyclovir 20 mg/kg po qid x 5 days (start within 24 hrs of rash) for patients at increased risk of moderate or severe varicella; chronic cutaneous or pulmonary diseases; chronic salicylate treatment (increased risk of Reye's syndrome)",
                "Acyclovir 800 mg po 5x/day x 5-7 days (start within 24 hrs of rash)",
                "Valacyclovir NAI 1000 mg po tid x 5-7 days",
                "Famciclovir NAI 500 mg po tid (probably effective but data lacking)",
                "Acyclovir 800 mg po 5x/day or 10 mg/kg IV q8h x 5 days",
                "Child age 2-12 years",
                "Adolescent, young adults",
                "Pregnancy (3rd trimester), pneumonia",
                "Immunocompromised",
                "Acyclovir 10-12 mg/kg (500 mg/M\u00b2) IV (infused over 1 hour) q8h x 7 days"
            ]
        },
        {
            "type": "header",
            "level": 1,
            "text": "Alternative Regimens"
        },
        {
            "type": "list",
            "items": [
                "None"
            ]
        },
        {
            "type": "header",
            "level": 1,
            "text": "Prevention"
        },
        {
            "type": "list",
            "items": [
                "See Varicella, Vaccine for indications, available products, dosing, and vaccine characteristics for pre- and post-exposure prevention.",
                "Prevention, post-exposure prophylaxis:",
                "Vaccinate all non-immune exposed persons; VZIG may be necessary in some situations."
            ]
        },
        {
            "type": "header",
            "level": 1,
            "text": "Comments"
        },
        {
            "type": "list",
            "items": [
                "Acyclovir slowed development and reduced number of new lesions and reduced duration of disease in children: 9 to 7.6 days (Ped Infect Dis J 21:739, 2002). Oral dose of acyclovir in children should not exceed 80 mg/kg/day or 3200 mg/day. Acyclovir decreased duration of fever, time to healing, and symptoms (Ann Intern Med 130:922, 1999).",
                "Varicella pneumonia associated with 41% mortality in pregnancy, acyclovir decreased incidence and severity (J Infect Dis 185:422, 2002). If varicella-susceptible mother exposed and respiratory symptoms develop within 10 days after exposure, start IV acyclovir.",
                "Immunocompromised patients. Disseminated primary varicella infection reported during infliximab therapy of rheumatoid arthritis (J Rheum 31:2517, 2004). Continuous infusion of high-dose acyclovir (2 mg/kg/hr) successful in 1 patient with severe hemorrhagic varicella. (N Engl J Med 336:732, 1997). Mortality high (43%) in AIDS patients (Int J Inf Dis 6:6, 2002).",
                "Review of therapeutics: Molecules 26: 1132, 2021",
                "Several new drugs in development: FV-100 (bicyclic nucleoside), ASP2151 (helices-primase inhibitor), valomaciclovir (acyclic guanosine H2G prodrug). Review (Adv Pharmacol 67:107, 2013)."
            ]
        }
    ]
}